ABBV AbbVie Inc

$186.06

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

About AbbVie Inc

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Website: https://www.abbvie.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1551152
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, US
Valuation
Market Cap
$306.02B
P/E Ratio
72.38
PEG Ratio
0.38
Price to Book
92.03
Performance
EPS
$2.39
Dividend Yield
3.79%
Profit Margin
7.59%
ROE
62.30%
Technicals
50D MA
$199.44
200D MA
$187.99
52W High
$216.66
52W Low
$148.19
Fundamentals
Shares Outstanding
2B
Target Price
$210.93
Beta
0.54

ABBV EPS Estimates vs Actual

Estimated
Actual

ABBV News & Sentiment

Apr 26, 2025 • Motley Fool SOMEWHAT-BULLISH
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Apr 26, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
Apr 25, 2025 • Motley Fool BULLISH
Why AbbVie Stock Topped the Market Today
A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie ( NYSE: ABBV ) stock an investor darling on Friday. The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the ...
Apr 25, 2025 • Benzinga SOMEWHAT-BULLISH
ROSEN, A TOP RANKED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
NEW YORK, April 25, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.
Apr 25, 2025 • Zacks Commentary SOMEWHAT-BULLISH
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
Apr 25, 2025 • Benzinga NEUTRAL
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) ( NASDAQ: CERE ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
NEW YORK, April 25, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( "Cerevel" or the "Company" ) CERE for violations of the ...
Sentiment Snapshot

Average Sentiment Score:

0.191
50 articles with scored sentiment

Overall Sentiment:

Bullish

ABBV Reported Earnings

Jan 31, 2025
Dec 31, 2024 (Pre market)
-0.1 Surprise
  • Reported EPS: $2.16
  • Estimate: $2.26
  • Whisper:
  • Surprise %: -4.3%
Oct 30, 2024
Sep 30, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $3.00
  • Estimate: $2.92
  • Whisper:
  • Surprise %: 2.7%
Jul 25, 2024
Jun 30, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $2.65
  • Estimate: $2.57
  • Whisper:
  • Surprise %: 3.1%
Apr 26, 2024
Mar 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $2.31
  • Estimate: $2.23
  • Whisper:
  • Surprise %: 3.6%
Feb 02, 2024
Dec 31, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $2.79
  • Estimate: $2.77
  • Whisper:
  • Surprise %: 0.7%
Oct 27, 2023
Sep 30, 2023 (Pre market)
0.09 Surprise
  • Reported EPS: $2.95
  • Estimate: $2.86
  • Whisper:
  • Surprise %: 3.1%
Jul 27, 2023
Jun 30, 2023 (Pre market)
0.1 Surprise
  • Reported EPS: $2.91
  • Estimate: $2.81
  • Whisper:
  • Surprise %: 3.6%
Apr 27, 2023
Mar 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $2.46
  • Estimate: $2.46
  • Whisper:
  • Surprise %: 0.0%
Feb 09, 2023
Dec 31, 2022 (Pre market)
0.04 Surprise
  • Reported EPS: $3.60
  • Estimate: $3.56
  • Whisper:
  • Surprise %: 1.1%

Financials